<PAGE> 1
Amended
Form 8-K
CURRENT REPORT
Pursuant to Section 13 of 15 (d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2000
Hemispherx Biopharma, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 027072 2-0845822
----------- ------------ ----------------
(State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification No.)
incorporation)
1617 JFK Blvd, #660, Philadelphia, Pennsylvania 19104
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (215) 988-0080
N/A
------------------------------------------------------------
Former name or former address, if changed since last report)
<PAGE> 2
Item 4. Changes in Registrant's Certifying Accountant.
On May 3, 2000, KPMG LLP ("KPMG") resigned from the client-auditor
relationship with the Registrant. On May 3, 2000, pursuant to the
prior decision of Registrant's Board and Audit Committee of the Board of
Directors to seek and retain the services of an independent accounting
firm other than KPMG, Registrant accepted the resignation of KPMG and
confirmed that the client-auditor relationship with the Company had
ceased.
KPMG's reports on the financial statements of Registrant for
the fiscal years ended December 31, 1998, and December 31, 1999, did not
contain any adverse opinion or any disclaimer of opinion and were not
qualified or modified as to uncertainty, audit scope or accounting
principles.
During the Registrant's two most recent fiscal years ending
December 31, 1998, and December 31, 1999, and the subsequent interim
period through May 3, 2000, there were no "reportable events" as
described in Items 304(a)(l)(iv) and (v) of Regulation S-K and no
disagreements between the Registrant and KPMG on any matter of accounting
principles or practice, financial statement disclosure or auditing scope
of procedure which, if not resolved to the satisfaction of KPMG would
have caused KPMG to make a reference to the subject matter thereof in
connection with its reports.
On June 5, 2000, Registrant engaged the services of BDO
Seidman, LLP as the Registrant's Independent Accountants. As the
Independent Accountants, BDO Seidman, LLP will audit the Consolidated
Financial Statements and provide other professional services as may be
required by the Registrant.
The Registrant's Board of Directors, with the approval of
Registrant's audit committee, authorized the Company to retain the
services of BDO Seidman, LLP.
Incorporated by reference are Form 8-Ks filed by the
Registrant with the Securities and Exchange Commission on May 10, 2000,
and as amended on May 18, June 6, and, July 12, 2000 to include the
response of former Registrant's Independent Accountants.
<PAGE> 3
Item 7. Financial Statements and Exhibits.
The following exhibit is being filed with the Form 8-K
report:
Exhibit No. Description
----------- -------------------------------
16 Letter dated July 13, 2000 from
KPMG LLP pursuant to Item
304 (a) (3) of Regulation S-K
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
HEMISPHERX BIOPHARMA, INC.
Dated: July 13, 2000 By: / s / W. A. Carter, M.D.
W. A. Carter, M.D.
Chairman/CEO/President
<PAGE> 4
LETTER OF FORMER ACCOUNTANTS
Securities and Exchange Commission
Washington, D.C. 20549
July 13, 2000
We were previously principal accountants for Hemispherx Biopharma, Inc.
and, under the date of February 19, 2000, we reported on the consolidated
financial statements of Hemispherx Biopharma, Inc. and subsidiaries as of
and for the years ended December 31, 1999 and 1998. We have read
Hemispherx Biopharma, Inc.'s statements included under Item 4 of its
Amended 8-K dated July 12, 2000, and we agree with such statements,
except that we are not in a position to agree or disagree with Hemispherx
Biopharma, Inc.'s statements in paragraph one of Item 4 regarding the
Board of Directors and the Audit Committee's decision to seek and retain
the services of an independent accounting firm or with the statements
contained in paragraphs four and five of Item 4.
Very truly yours,
/X/ KPMG LLP
